ID
22298
Description
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Non-measurable Disease (Non-target Lesions) Assessment Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast
Lien
https://clinicaltrials.gov/ct2/show/NCT00078572
Mots-clés
Versions (1)
- 29/05/2017 29/05/2017 -
Téléchargé le
29 mai 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Non-measurable Disease NCT00078572
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Non-measurable Disease NCT00078572
Description
Assessment 2
Alias
- UMLS CUI-1
- C2986547
- UMLS CUI-2
- C0220825
- UMLS CUI-3
- C1518373
- UMLS CUI-4
- C0012634
Description
Date
Type de données
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0220825
- UMLS CUI [1,3]
- C0221198
Description
Longest Diameter
Type de données
float
Unités de mesure
- mm
Alias
- UMLS CUI [1,1]
- C0552406
- UMLS CUI [1,2]
- C0221198
Description
Method
Type de données
text
Alias
- UMLS CUI [1,1]
- C0871511
- UMLS CUI [1,2]
- C0221198
Description
Lesion Status
Type de données
text
Alias
- UMLS CUI [1,1]
- C0449438
- UMLS CUI [1,2]
- C0221198
Similar models
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Non-measurable Disease NCT00078572
C0220825 (UMLS CUI-2)
C1518373 (UMLS CUI-3)
C0012634 (UMLS CUI-4)
C0221198 (UMLS CUI [1,2])
C1710477 (UMLS CUI [2])
C0221198 (UMLS CUI [1,2])
C0450429 (UMLS CUI [1,2])
C0805701 (UMLS CUI [1,2])
C0221198 (UMLS CUI [2,1])
C0450429 (UMLS CUI [2,2])
C0220825 (UMLS CUI [1,2])
C0221198 (UMLS CUI [1,3])
C0221198 (UMLS CUI [1,2])
C0220825 (UMLS CUI-2)
C1518373 (UMLS CUI-3)
C0012634 (UMLS CUI-4)
C0220825 (UMLS CUI [1,2])
C0221198 (UMLS CUI [1,3])
C0221198 (UMLS CUI [1,2])
Aucun commentaire